Usher syndrome is one of the many rare genetic disorders, and is primarily characterized by deafness. This deafness is noticed due to the impaired ability of the auditory nerves and inner ear to transmit sound input to the brain; this is known as sensorineural hearing loss. Moreover, it is accompanied by retinitis pigmentosa, which is a disorder that affects the retina of the eye and causes progressive loss of vision. As identified by researchers, three clinical types of Usher syndrome, designated as type I, type II and type III, are prevalent globally. The severity of the symptoms and the age at which the symptoms of the disorder appear are determined by the underlying genetic cause. Usher syndrome is known to be inherited as an autosomal recessive genetic trait.
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the usher syndrome market.
Top Impacting Factors
Alarming increase in the cases of genetic and inherited disorders globally acts as a key driving force of the global usher syndrome market.
There is an inclination toward improvisation of surgeries, minimally invasive surgeries, and awareness about the disease among many people which may influence the usher syndrome market positively. Moreover, an increase in investment, rise in R&D activities in the field of genetic and inherited disorders, and upsurge in population positively affect the market.
Advancement in hearing kits and cochlear implants, which can improve hearing augment the growth of the market. However, lack of awareness and lack of disease etiology in many developing countries of the world hamper the market growth. In addition, low healthcare budget in some countries and inaccessibility & unaffordability of cochlear implants to many underserved people act as restricting factors of the Usher syndrome market.
Market Trends
The Usher syndrome market is expected to exhibit high growth potential during the forecast period. This is attributed to rise in prevalence of inherited disorders.
The major players in the usher syndrome market are Century Hearing Aids, MeiraGTx, Zounds Hearing and Sivantos Pte. Ltd., and Johnson & Johnson Services, Inc.
In December 2020, the FDA granted orphan drug designation for the treatment of retinitis pigmentosa, which often affects people suffering from Usher syndrome. The FDA granted special status to a new cell therapy that can chemically convert cells into photoreceptor-like cells. These photoreceptor-like cells help in partial restoration of visual function and pupil reflex.
- Eyevensys S.A.S., a biotechnology company, received the FDA orphan drug designation for EYS611, which is targeted to treat retinitis pigmentosa. Eyevensys has been granted a window of seven years to exclusively develop EYS611.
- LambdaVision, Inc., another biotech company, is set to launch its artificial retina technology with Space Tango, its engineering partner. The research of Lambdavision is exploring the advantages of microgravity for the production of its artificial retina.
- Oncugen, Inc., a clinical-stage company, studied the potency of a novel modifier gene therapy. This therapy elicits therapeutic effects in the immediate and early stages of retinitis pigmentosa.
Key Benefits of the Report
- This study presents the analytical depiction of the usher syndrome industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the market share.
- The current market is quantitatively analyzed to highlight the market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in the coming years.
Questions answered in the Usher Syndrome Report
- Which are the leading players active in the Usher syndrome market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the Usher syndrome market in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is "Usher syndrome"?
- What is the "Usher syndrome" market prediction in the future?
- What are the current trends and predicted trends?
Usher Syndrome Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Diagnosis |
|
 By Treatment |
|
 By End-Users |
|
 By DISTRIBUTION CHANNEL |
|
 By Region |
|
 Key Market Players | Johnson & Johnson Services, Inc., ProQR Therapeutics NV Sanofi Corporation, MeiraGTx, Nobelpharma Co., Ltd., Amgen, Inc., Cochlear Ltd., Editas Medicine, Inc., Advanced Bionics AG, Zounds Hearing and Sivantos Pte. Ltd., Century Hearing Aids |
Loading Table Of Content...
